These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 7791152)

  • 21. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH; Bingham SJ; Seto Y; McGonagle D; Bejarano V; White J; Emery P
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
    Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
    Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
    Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT
    J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression.
    Haroon N; Srivastava R; Misra R; Aggarwal A
    J Rheumatol; 2008 Jun; 35(6):975-8. PubMed ID: 18464312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T; Pincus T
    J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tumor necrosis factor-alpha and kidney damage in rheumatoid arthritis].
    Tsybul'ko SV; Baranov AA; Borodin AG; Korshunov NI; Kirdianov SIu
    Ter Arkh; 2001; 73(5):8-11. PubMed ID: 11517757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients.
    Ranganath VK; Elashoff DA; Khanna D; Park G; Peter JB; Paulus HE;
    J Rheumatol; 2005 Jun; 32(6):1040-2. PubMed ID: 15940764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rate.
    Yazici Y; Pincus T; Kautiainen H; Sokka T
    J Rheumatol; 2004 Sep; 31(9):1723-6. PubMed ID: 15338490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical measures in rheumatoid arthritis: which are most useful in assessing patients?
    Ward MM
    J Rheumatol; 1994 Jan; 21(1):17-27. PubMed ID: 7864914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of TNF-alpha, TNF-alphaRI, TNF-alphaRII and IL-12 in treated rheumatoid arthritis patients.
    Ebrahimi AA; Noshad H; Sadreddini S; Hejazi MS; Mohammadzadeh Sadigh Y; Eshraghi Y; Ghojazadeh M
    Iran J Immunol; 2009 Sep; 6(3):147-53. PubMed ID: 19801788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor.
    Roubenoff R; Roubenoff RA; Ward LM; Holland SM; Hellmann DB
    J Rheumatol; 1992 Oct; 19(10):1505-10. PubMed ID: 1464859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.